# Stratifying Rett syndrome patient populations to evaluate the efficacy of genetic and pharmacological therapeutic interventions

> **NIH NIH F31** · VANDERBILT UNIVERSITY · 2021 · $30,751

## Abstract

PROJECT SUMMARY/ABSTRACT
Loss-of-function mutations in the transcription factor methyl-CpG-binding protein 2 (MeCP2) result in the X-
linked neurodevelopmental disorder Rett syndrome (RTT). The growth in research surrounding this monogenic
disorder has resulted in development of preclinical models that recapitulate phenotypes such as stereotypic
behavior of repetitive hand wringing, breathing abnormalities and deficits in motor and cognition. However,
effective therapeutic treatments remain lacking. This can be attributed to the complex functions and diverse
targets of MeCP2. Therefore, this research proposal has been developed to explore two arms of the
therapeutic discovery efforts: genetic and pharmacological interventions. The design of this proposal provides
the opportunity for the applicant to develop a breadth of training in neurophysiology and neuropharmacology
spanning molecular, electrophysiological and behavioral techniques.
In recent years, normalizing MeCP2 expression using gene therapy has garnered significant attention as a
one-size fits all intervention for RTT. However, difference in MECP2 pathological mutations between patients
introduces subpopulations that could further complicate an already narrow therapeutic index. Specifically, we
hypothesize that patients with hypomorphic mutations could be at a greater risk for adverse effects (AEs) that
mimic phenotypes of a related disorder, MECP2 Duplication syndrome. Behavioral and electrophysiological
presentations of these possible MeCP2-mediated AEs are proposed to be evaluated by generating mice that
harbor both a specific hypomorphic mutation and express a wild-type MeCP2 allele.
To complement the genetic approach and circumvent these possible MeCP2-mediated AEs, a downstream
target of MeCP2, metabotropic glutamate receptor 3 (mGlu3), will be targeted pharmacologically. mGlu3 has
been demonstrated to have a functional role in cognition, and its expression has been consistently shown to be
decreased in mouse models of RTT. We have preliminary data that suggests mGlu3 plays a significant role in
long-term synaptic plasticity; additionally, we have generated data showing that mGlu3 expression is clinically
relevant, as mGlu3 mRNA expression is significantly decreased in brain autopsy samples from patients
clinically diagnosed with RTT. Therefore, we hypothesize that decreased mGlu3 expression contributes to
cognitive phenotypes in RTT and that pharmacologically potentiating mGlu3 function will improve these
phenotypes in RTT model mice.

## Key facts

- **NIH application ID:** 10210230
- **Project number:** 5F31MH119699-03
- **Recipient organization:** VANDERBILT UNIVERSITY
- **Principal Investigator:** Sheryl Anne Daguimol Vermudez
- **Activity code:** F31 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $30,751
- **Award type:** 5
- **Project period:** 2019-08-01 → 2022-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10210230

## Citation

> US National Institutes of Health, RePORTER application 10210230, Stratifying Rett syndrome patient populations to evaluate the efficacy of genetic and pharmacological therapeutic interventions (5F31MH119699-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10210230. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*